We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Calliditas Therapeutics Ab | LSE:0A5R | London | Ordinary Share | SE0010441584 | CALLIDITAS THERAPEUTICS ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 926 | - |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 805.74M | -412.27M | -6.9196 | -1.09 | 449.83M |
From Apr 2021 to Apr 2024
STOCKHOLM, May 14, 2021 /PRNewswire/ -- On May 18th, 2021, Calliditas Therapeutics AB (publ) ("Calliditas") will publish its financial report for the first quarter of 2021, and at 2.30 pm CET will host a conference call to present and discuss the results.
The event will be hosted by the company's CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, and will be held in English. The presentation will be webcast live and will also be made available online on the Calliditas website after the call.
Webcast link: https://tv.streamfabriken.com/calliditas-therapeutics-q1-2021
Teleconference: SE: +46850558366 UK: + 443333009271 US: + 18335268381
For further information, please contact:
Marie Galay, IR Manager, Calliditas
Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com
The information was sent for publication, through the agency of the contact person set out above, on May 14, 2021 at 2:00 p.m. CET.
About Calliditas
Calliditas Therapeutics is a biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas successfully reported top line data of its global Phase 3 study in IgAN in November of 2020 and, if approved, aims to commercialize Nefecon in the United States on its own and partner elsewhere. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit www.calliditas.com for further information.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/calliditas-therapeutics-to-host-conference-call-to-provide-business-update-for-the-first-quarter-of-,c3346790
The following files are available for download:
https://mb.cision.com/Main/16574/3346790/1417298.pdf | Q1 Inv Call ENG |
View original content:http://www.prnewswire.com/news-releases/calliditas-therapeutics-to-host-conference-call-to-provide-business-update-for-the-first-quarter-of-2021-301291671.html
SOURCE Calliditas Therapeutics
Copyright 2021 PR Newswire
1 Year Calliditas Therapeutics Ab Chart |
1 Month Calliditas Therapeutics Ab Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
